Wire · operational-macro
FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 October 2026 · Fusion42 review
The FDA has granted accelerated approval for the immunotherapy Jemperli (dostarlimab-gxly) to treat previously untreated stage II or III locally advanced rectal cancer with dMMR or MSI-H biomarkers, potentially allowing patients to avoid chemotherapy, radiation, and surgery.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.
◆ ◆ The Wire takeaway
The FDA’s fast-tracked approval of Jemperli creates a clear path to bypass traditional rectal cancer treatments that disrupt patients’ lives. You can now focus on developing targeted immunotherapies that may replace surgery and chemo as the standard of care.
◆ Coverage
5 sources · 19 Oct 2026
◆ Related on Wire
◆ Topics